Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

AstraZeneca Withdraws Zactima from Consideration of FDA Approval for Advanced NSCLC
Author
Howard (Jack) West, MD

AstraZeneca (AZ) just issued a press release noting that they are withdrawing their application for the "multi-kinase inhibitor" Zactima (vandetanib) to receive FDA approval to be given along with chemo in advanced NSCLC right now. Zactima is a pill that has the potential to block both the EGFR and VEGF (angiogenic) pathway, and I've described some of the larger clinical trials being pursued by AstraZeneca with Zactima in a prior post. I also covered the more complete presentations of the data earlier this year and why I felt that the benefits of Zactima appeared quite underwhelming, while member and GRACE board member Neil Berch made an argument favoring a meaningful benefit with Zactima.

Several months ago, AZ had filed an application with the FDA for approval of Zactima along with chemo, based on the modestly positive results of the ZODIAC and ZEAL trials. Though I don't know any back story, I presume the signals that they were getting were primarily that there were more people underwhelmed than impressed by these results, because they've withdrawn that application now.

One of the conlcusions that Neil and I agreed on was that it would be important and helpful to see a survival benefit in the ZEPHYR trial, which compares Zactima to placebo in patients with advanced NSCLC who have previously received an oral EGFR inhibitor. The results of that trial are anticipated to be released in the next several months, so AZ may be prioritizing its efforts and resources for Zactima by channeling them toward a campaign as a single agent therapy rather than combined with chemo.

I look forward to learning the results of the ZEPHYR trial, and we'll definitely discuss them when they become available.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on